IQM's Q-Exa Consortium Selected to Integrate German Quantum Computer Into HPC Supercomputer for the First Time
15.11.2021 20:44:00 EET | Business Wire | Press release
IQM Quantum Computers has been selected to provide a quantum computing system that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. The delivery is part of a €45.3 million consortium project. The project is funded by the German Federal Ministry of Education and Research (BMBF) with €40.1 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115006110/en/
Picture: Federal Minister Anja Karliczek hands over the grant certificate to Jan Goetz, CEO of IQM Picture credit: BMBF/Hans-Joachim Rickel
The highly interdisciplinary consortium with experts from quantum physics and computer science, from research centers and industry, will integrate a quantum computing system provided by IQM into an HPC environment via a research purchase. This will be the first time that a gate-based quantum system will be coupled with an HPC system, making quantum acceleration of HPC applications a reality.
Quantum computers have significant potential for solving a certain class of scientific and industrial problems that cannot be addressed by classical supercomputers. To meet this challenge, HPC centers around the world are looking for ways to integrate quantum accelerators into their computing infrastructure. The ability to provide on-site solutions for quantum computing in conjunction with supercomputers is essential for the development of cutting-edge high-tech solutions from Europe. The main goal of the Q-Exa project is to establish such solutions and thus strengthen the application- related use of quantum technologies from Germany.
IQM will work with Leibniz Supercomputing Centre, LRZ - one of Germany's three national supercomputing centers, Europe's leading HPC and quantum system provider (Atos) and one of Germany's leading innovators of quantum computing applications (HQS) on this project.
Q-Exa's collaborative approach creates strong synergies with other research projects in the German and European ecosystem. The previously announced BMBF project DAQC benefits from novel simulators and fits seamlessly into the concept of the Q-Exa Co-Design Lab. The new Co-Design lab will accelerate the path to self-sustaining quantum computing, the so-called quantum advantage, through industry partnerships. This approach is in line with other German industry efforts, such as the recently formed QUTAC consortium. On the application side, research consortia such as the BMBF projects QLindA, MANIQU and other initiatives support development as industrial use cases can be tested on the Q-Exa demonstrators. Finally, the Q-Exa project supports the European strategy based on integrating quantum computing accelerators into European HPC centers. With Q-Exa, Germany can make an active contribution to these European efforts.
Federal Research Minister Anja Karliczek says: "The international race in the field of quantum technologies is in full swing. Germany and the European Union must do their utmost to keep pace in order to guarantee our technological sovereignty. We want to be able to autonomously use the technology and develop it further. The Q-Exa project opens a new promising chapter on our path to a quantum computer 'made in Germany'. Integrating a quantum computer with the infrastructure of the Leibniz Supercomputing Centre harbours enormous potential for science and industry. The project will contribute to bringing quantum computers close to practice and to provide specific application scenarios for users in science and industry. I am delighted that by launching the project we have reached the first milestone on the way towards a competitive quantum computer 'made in Germany'."
Dr. Jan Goetz, CEO of IQM Quantum Computers remarks: "We are pleased to deliver a quantum computing system to LRZ and to work with the consortium partners to integrate this system into a production-grade HPC environment. I am grateful to the Federal Ministry of Education and Research in Germany, which has given us the necessary trust and support for this ambitious project. Together we will work hard to make European technology competitive and develop the most promising hardware solutions for quantum computing here in Germany".
Prof. Dr. Dieter Kranzlmuller, Chairman of the Board of Directors, LRZ, points out: “The Q-Exa project is key for our activities within the LRZ Quantum Integration Centre (QIC) and the Munich Quantum Valley (MQV). Working with this extremely competitive consortium, we will be able to set European standards that are competitive on a global scale. Ultimately, this will be for the benefit of society as the integration of quantum computing into supercomputers, in particular on the exascale level, will speed up and open vast new research possibilities. It will bring quantum computing to users – both in academia and in industry. And now is exactly the right time to realize this in a data center environment”.
“Technological sovereignty in strategic areas like quantum computing is critical for Europe. With our Quantum Learning Machine (QLM) and strong startup partners like IQM, Atos is proud to contribute to this joint effort. It is time to build the first German quantum computer, connected to an HPC datacenter through our QLM”, says Udo Littke, Head of Atos Central Europe.
„Quantum computers will accelerate scientific progress and the development of new technologies in many areas. Chemistry, physics and biology can potentially profit from the ability to perform improved quantum mechanical simulations. Therefore, it is the next logical step to integrate quantum computers into high performance computer centers like the LRZ. We are looking very much forward to connect the end users of the LRZ with the necessary software tools to make full use of the coming computational capabilities”, says Dr. Michael Marthaler, CEO HQS Quantum Simulations GmbH.
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to develop application-specific quantum processors by the German Ministry of Education and Research in February 2021.
IQM has raised €71 million from private and public funding and has offices in Munich, Germany; Espoo, Finland; and Bilbao, Spain.
For more information, visit www.meetiqm.com.
IQM: Facts and Figures
- Number of employees currently (November 2021): 130+ employees
- Funding: Over € 71 Million from private and public funding
- Founding Year: 2018
Founders:
-
Dr. Jan Goetz, CEO, Co-founder of IQM
-
Dr. Kuan Yen Tan, CTO, Co-founder of IQM
- Prof. Mikko Mottonen, Chief scientist, Co-founder of IQM
- Dr. Juha Vartiainen, COO, Co-founder of IQM
For more information, visit www.meetiqm.com.
Registered offices:
IQM Finland Oy Keilaranta 19
02150 Espoo Finland
IQM Germany GmbH Nymphenburgerstr. 86 80636 Munchen Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115006110/en/
Contact information
Media Contact:
Raghunath Koduvayur, Head of Marketing and Communications
Raghunath@meetiqm.com, +358504876509
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
